Lysy Philippe-A, Najimi Mustapha, Stephenne Xavier, Bourgois Annick, Smets Francoise, Sokal Etienne-M
Pediatric Hepatology and Cell Therapy, Universite Catholique de Louvain, Cliniques Saint Luc, 10 av. Hippocrate, Brussels B-1200, Belgium.
World J Gastroenterol. 2008 Jun 14;14(22):3464-70. doi: 10.3748/wjg.14.3464.
Liver cell transplantation is an attractive technique to treat liver-based inborn errors of metabolism. The feasibility and efficacy of the procedure has been demonstrated, leading to medium term partial metabolic control of various diseases. Crigler-Najjar is the paradigm of such diseases in that the host liver is lacking one function with an otherwise normal parenchyma. The patient is at permanent risk for irreversible brain damage. The goal of liver cell transplantation is to reduce serum bilirubin levels within safe limits and to alleviate phototherapy requirements to improve quality of life. Preliminary data on Gunn rats, the rodent model of the disease, were encouraging and have led to successful clinical trials. Herein we report on two additional patients and describe the current limits of the technique in terms of durability of the response as compared to alternative therapeutic procedures. We discuss the future developments of the technique and new emerging perspectives.
肝细胞移植是一种治疗基于肝脏的先天性代谢缺陷的有吸引力的技术。该手术的可行性和有效性已得到证实,可实现对各种疾病的中期部分代谢控制。克里格勒-纳贾尔综合征是这类疾病的典型代表,其宿主肝脏缺乏一种功能,而实质组织在其他方面正常。患者面临不可逆转的脑损伤的永久风险。肝细胞移植的目标是将血清胆红素水平降低到安全范围内,并减轻光疗需求,以提高生活质量。关于该疾病的啮齿动物模型——冈恩大鼠的初步数据令人鼓舞,并促成了成功的临床试验。在此,我们报告另外两名患者的情况,并描述与替代治疗方法相比,该技术在反应持久性方面目前的局限性。我们讨论了该技术的未来发展和新出现的观点。